Prevalence of Sarcopenia and Its Relationships between Physical Performance and Sarcopenia in Patients with Heart Failure: a Preliminary Cross-Sectional Study
Keywords:
heart failure, sarcopenia, physical performanceAbstract
Heart failure is an abnormality in the function of heart. This leads to dyspnea, fatigue, edema at limbs. Patients with heart failure are associated with sarcopenia, which is a major problem with exercise endurance, physical performance, mental health problems and reduce the quality of life. Therefore, this study aimed to explore the prevalence of sarcopenia and the relationship between physical performance and sarcopenia in patients with heart failure. One hundred participants; average age 57 years (ages 35 to 75 years old) both males and females were recruited to the study. Participants were performed the physical performance consisted of handgrips strength, skeletal muscle mass index, gait speed, respiratory muscle strength, and 5-time sit to stand. All data were analyzed by SPSS Statistics program. ANOVA and post hoc test with Bonferroni were performed to compare between sarcopenia, possibility of sarcopenia and no sarcopenia. Spearman rank correlation was used to explore the relationship between sarcopenia and physical performance. This study found the prevalence of sarcopenia was 15.0%, the prevalence of possible sarcopenia was 12.0%. Factors significantly associated with sarcopenia in heart failure were sex, age, body mass index, skeletal muscle mass index, handgrips strength, gait speed, respiratory muscle strength and 5-time sit to stand (p<0.05). In addition, these relationships were also remained after adjusted for age and sex. Therefore, this study found the prevalence of sarcopenia was 15.0%. Advanced age, low skeletal muscle mass index, poor handgrip strength, slow gait speed, reduced inspiratory muscle strength and slower sit-to-stand times were observed in chronic heart failure patients with sarcopenia. In addition, the relationship between sarcopenia and physical performance were observed in patients with heart failure.
Downloads
References
ปิยภัทร ชุณหรัศมิ์ , ธีรภัทร ยิ่งชนม์เจริญ, ระพีพล กุญชร ณ อยุธยา, บรรณาธิการ. แนวทางเวชปฏิบัติเพื่อการวินิจฉัย และการดูแลรักษาผู้ป่วยภาวะหัวใจล้มเหลว พ.ศ. 2562 (Heart Failure Council of Thailand (HFCT): 2019 heart failure guideline). กรุงเทพมหานคร: เนคสเตปดีไซน์; 2562.
McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021;42(36):3599-726.
Ariyachaipanich A, Krittayaphong R, Kunjara Na Ayudhya R, Yingchoncharoen T, Buakhamsri A, et al. Heart Failure Council of Thailand (HFCT) 2019 heart failure guideline: introduction and diagnosis. J Med Assoc Thai 2019;102(2):231-9.
Chen LK, Liu LK, Woo J, Assantachai P, Auyeung TW, Bahyah KS, et al. Sarcopenia in Asia: consensus report of the Asian working group for sarcopenia. J Am Med Dir Assoc 2014;15(2):95-101.
Lena A, Anker MS, Springer J. Muscle wasting and sarcopenia in heart failure—the current state of science. Int J Mol Sci 2020;21(18):6549.
Hammond MD, Bauer KA, Sharp JT, Rocha RD. Respiratory muscle strength in congestive heart failure. Chest 1990;98(5):1091-4.
Canteri AL, Gusmon LB, Zanini AC, Nagano FE, Rabito EI, Petterie RR, et al. Sarcopenia in heart failure with reduced ejection fraction. Am J Cardiovasc Dis 2019;9(6):116-26.
Marzetti E, Calvani R, Tosato M, Cesari M, Di Bari M, Cherubini A, et al. Sarcopenia: an overview. Aging Clin Exp Res 2017;29(1):11-7.
Chen LK, Woo J, Assantachai P, Auyeung TW, Chou MY, Iijima K, et al. Asian working group for sarcopenia: 2019 consensus update on sarcopenia diagnosis and treatment. J Am Med Dir Assoc 2020;21(3):300-7.
Tiedemann A, Shimada H, Sherrington C, Murray S, Lord S. The comparative ability of eight functional mobility tests for predicting falls in community-dwelling older people. Age Ageing 2008;37(4):430-5.
American Thoracic Society/European Respiratory Society. ATS/ERS Statement on respiratory muscle testing. Am J Respir Crit Care Med 2002;166(4):518- 624.
Suzuki T, Palus S, Springer J. Skeletal muscle wasting in chronic heart failure. ESC Heart Fail 2018;5(6):1099- 107.
Meyer FJ, Borst MM, Zugck C, Kirschke A, Schellberg D, Kübler W, et al. Respiratory muscle dysfunction in congestive heart failure: clinical correlation and prognostic significance. Circulation 2001;103(17):2153-8.
Emami A, Saitoh M, Valentova M, Sandek A, Evertz R, Ebner N, et al. Comparison of sarcopenia and cachexiain men with chronic heart failure: results from the Studies Investigating Co-morbidities Aggravating Heart Failure (SICA-HF). Eur J Heart Fail 2018;20(11): 1580-7.
Eulster S, Tacke M, Sandek A, Ebner N, Tschope C, Doehner W, et al. Muscle wasting in patients with chronic heart failure: results from the studies investigating co-morbidities aggravating heart failure (SICA-HF). Eur Heart J 2013;34(7):512-9.
Rolland Y, Czerwinski S, Abellan Van Kan G, Morley JE, Cesari M, Onder G, et al. Sarcopenia: its assessment, etiology, pathogenesis, consequences and future perspectives. J Nutr Health Aging 2008;12(7):433-50.
ชิติมา กุลชนะรัตน์, กรอนงค์ ยืนยงชัยวัฒน์. การทบทวน วรรณกรรมอย่างเป็นระบบเรื่องความชุกและปัจจัยที่มีความ สัมพันธ์ต่อการเกิดภาวะมวลกล้ามเนื้อน้อยในผู้ป่วยที่มีภาวะหัวใจล้มเหลว. วชิรเวชสารและวารสารเวชศาสตร์เขตเมือง 2563;64(5):333-44.
Konishi M, Kagiyama N, Kamiya K, Saito H, Saito K, Ogasahara Y, et al. Impact of sarcopenia on prognosis in patients with heart failure with reduced and preserved ejection fraction. European Journal of Preventive Cardiology 2021;28(9):1022-9.
Pinheiro PA, Carneiro JAO, Coqueiro RS, Pereira R, Fernandes MH. Chair stand test as simple tool for sarcopenia screening in elderly women. J Nutr Health Aging 2016;20(1):56-9.
Lee K, Davis MA, Marcotte JE, Pressler SJ, Liang J, Gallagher NA, et al. Falls in community-dwelling older adults with heart failure: A retrospective cohort study. Heart Lung 2020;49(3):238-50.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
